UBE2V1 (ubiquitin conjugating enzyme E2 variant 1) is an unconventional E2 enzyme that lacks intrinsic catalytic activity but functions as an essential component of the ubiquitin-proteasome system 1. Operating as a heterodimer with UBE2N/Ubc13, UBE2V1 catalyzes non-canonical Lys-63-linked polyubiquitination that activates NF-κB signaling and does not target proteins for proteasomal degradation 2. This enzyme plays critical roles in multiple cellular processes: it regulates protein aggregation and quality control in cardiomyocytes and oocytes 13, mediates fibroblast growth factor 2-induced angiogenesis in endothelial cells 4, and facilitates immune responses through Lin28a ubiquitination in bladder cancer 5. Functionally, UBE2V1 promotes protein aggregate formation by enhancing K63-ubiquitination and impairing ubiquitin-proteasome system performance 1. In disease contexts, UBE2V1 dysregulation associates with poor prognosis across multiple cancers: elevated expression promotes colorectal cancer metastasis by suppressing autophagy through Sirt1 degradation 2, while upregulation in cervical cancer correlates with advanced clinical stages and shorter survival 6. UBE2V1 also participates in pancreatic cancer progression via the miR-4689/UBE2V1/p53 axis 7. These findings establish UBE2V1 as a pivotal regulator of proteostasis and signaling with significant implications for age-related and neoplastic diseases.